ATS 2022 Conference News Preview - Insert 1B

The FIRST & ONLY biologic approved for severe asthma
without phenotypic or biomarker limitations1
Find out more about the efficacy
and safety data of TEZSPIRE
in an all-comer population.
IMPORTANT SAFETY INFORMATION (cont'd)
WARNINGS AND PRECAUTIONS (cont'd)
Acute Asthma Symptoms or Deteriorating Disease
TEZSPIRE should not be used to treat acute asthma
symptoms, acute exacerbations, acute bronchospasm,
or status asthmaticus.
Abrupt Reduction of Corticosteroid Dosage
Do not discontinue systemic or inhaled corticosteroids
abruptly upon initiation of therapy with TEZSPIRE.
Reductions in corticosteroid dose, if appropriate, should
be gradual and performed under the direct supervision
of a physician. Reduction in corticosteroid dose may be
associated with systemic withdrawal symptoms and/or
unmask conditions previously suppressed by systemic
corticosteroid therapy.
Parasitic (Helminth) Infection
It is unknown if TEZSPIRE will influence a patient's
response against helminth infections. Treat patients
with pre-existing helminth infections before initiating
therapy with TEZSPIRE. If patients become infected while
receiving TEZSPIRE and do not respond to anti-helminth
treatment, discontinue TEZSPIRE until infection resolves.
Live Attenuated Vaccines
The concomitant use of TEZSPIRE and live attenuated
vaccines has not been evaluated. The use of live
attenuated vaccines should be avoided in patients
receiving TEZSPIRE.
tezspirehcp.com
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥3%) are
pharyngitis, arthralgia, and back pain.
USE IN SPECIFIC POPULATIONS
There are no available data on TEZSPIRE use in pregnant
women to evaluate for any drug-associated risk of major
birth defects, miscarriage, or other adverse maternal
or fetal outcomes. Placental transfer of monoclonal
antibodies such as tezepelumab-ekko is greater during
the third trimester of pregnancy; therefore, potential
effects on a fetus are likely to be greater during the third
trimester of pregnancy.
INDICATION
TEZSPIRE is indicated for the add-on maintenance
treatment of adult and pediatric patients aged 12 years
and older with severe asthma.
TEZSPIRE is not indicated for the relief of acute
bronchospasm or status asthmaticus.
Full Prescribing Information including Patient
Information.
You may report side effects related to AstraZeneca
products by clicking here.
Reference: 1. TEZSPIRETM (tezepelumab-ekko) [package insert].
Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca
Pharmaceuticals LP; December 2021.
TEZSPIRE is a trademark of Amgen Inc. and AstraZeneca.
©2022 AstraZeneca. All rights reserved. US-61841 Last Updated 3/22
Aim higher.
https://www.tezspirehcp.com/ http://www.tezspirehcp.com
ATS 2022 Conference News Preview

Table of Contents for the Digital Edition of ATS 2022 Conference News Preview
